Capricor Therapeutics (NASDAQ:CAPR) Price Target Cut to $22.00 by Analysts at Oppenheimer

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) had its target price reduced by equities researchers at Oppenheimer from $43.00 to $22.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an "outperform" rating on the biotechnology company's stock. Oppenheimer's price objective would indicate a potential upside of 201.95% from the stock's previous close.

Several other brokerages have also commented on CAPR. Wall Street Zen lowered Capricor Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 22nd. Cantor Fitzgerald reiterated an "overweight" rating and issued a $30.00 price target on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Roth Capital reiterated a "buy" rating and issued a $31.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, June 17th. Finally, HC Wainwright reissued a "buy" rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research note on Friday, June 13th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $36.67.

Capricor Therapeutics Price Performance

Capricor Therapeutics stock traded down $0.97 during midday trading on Monday, reaching $7.29. The company had a trading volume of 3,450,846 shares, compared to its average volume of 1,908,228. The firm's fifty day simple moving average is $10.95 and its 200-day simple moving average is $12.51. The company has a market capitalization of $332.82 million, a P/E ratio of -5.11 and a beta of 0.85. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The biotechnology company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.20). The firm had revenue of $2.73 million for the quarter, compared to analysts' expectations of $3.16 million. Capricor Therapeutics had a negative return on equity of 62.42% and a negative net margin of 181.71%. During the same quarter in the prior year, the business earned ($0.31) earnings per share. On average, analysts expect that Capricor Therapeutics will post -1.21 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Farallon Capital Management LLC acquired a new position in Capricor Therapeutics in the 4th quarter valued at $31,056,000. Vanguard Group Inc. boosted its position in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock valued at $31,420,000 after acquiring an additional 700,243 shares during the period. Woodline Partners LP acquired a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $8,693,000. Octagon Capital Advisors LP bought a new position in Capricor Therapeutics during the first quarter worth about $4,270,000. Finally, Altium Capital Management LLC increased its position in Capricor Therapeutics by 150.5% during the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock worth $9,853,000 after acquiring an additional 429,000 shares during the period. 21.68% of the stock is owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.